214 related articles for article (PubMed ID: 38765391)
21. GPNMB expression identifies TSC1/2/mTOR-associated and MiT family translocation-driven renal neoplasms.
Salles DC; Asrani K; Woo J; Vidotto T; Liu HB; Vidal I; Matoso A; Netto GJ; Argani P; Lotan TL
J Pathol; 2022 Jun; 257(2):158-171. PubMed ID: 35072947
[TBL] [Abstract][Full Text] [Related]
22. Overview of the 2022 WHO Classification of Thyroid Neoplasms.
Baloch ZW; Asa SL; Barletta JA; Ghossein RA; Juhlin CC; Jung CK; LiVolsi VA; Papotti MG; Sobrinho-Simões M; Tallini G; Mete O
Endocr Pathol; 2022 Mar; 33(1):27-63. PubMed ID: 35288841
[TBL] [Abstract][Full Text] [Related]
23. Towards a new WHO classification of renal cell tumor: what the clinician needs to know-a narrative review.
Cimadamore A; Cheng L; Scarpelli M; Massari F; Mollica V; Santoni M; Lopez-Beltran A; Montironi R; Moch H
Transl Androl Urol; 2021 Mar; 10(3):1506-1520. PubMed ID: 33850785
[TBL] [Abstract][Full Text] [Related]
24. The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testing.
Cajaiba MM; Dyer LM; Geller JI; Jennings LJ; George D; Kirschmann D; Rohan SM; Cost NG; Khanna G; Mullen EA; Dome JS; Fernandez CV; Perlman EJ
Cancer; 2018 Aug; 124(16):3381-3389. PubMed ID: 29905933
[TBL] [Abstract][Full Text] [Related]
25. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.
Moch H; Cubilla AL; Humphrey PA; Reuter VE; Ulbright TM
Eur Urol; 2016 Jul; 70(1):93-105. PubMed ID: 26935559
[TBL] [Abstract][Full Text] [Related]
26. Morphologic, Molecular, and Taxonomic Evolution of Renal Cell Carcinoma: A Conceptual Perspective With Emphasis on Updates to the 2016 World Health Organization Classification.
Udager AM; Mehra R
Arch Pathol Lab Med; 2016 Oct; 140(10):1026-37. PubMed ID: 27684973
[TBL] [Abstract][Full Text] [Related]
27. Translocation carcinomas of the kidney.
Argani P
Genes Chromosomes Cancer; 2022 May; 61(5):219-227. PubMed ID: 34704642
[TBL] [Abstract][Full Text] [Related]
28. [International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia 2012].
Hes O
Cesk Patol; 2014; 50(4):137-41. PubMed ID: 25418900
[TBL] [Abstract][Full Text] [Related]
29. Merlin immunohistochemistry is useful in diagnosis of tumours within the spectrum of biphasic hyalinizing psammomatous renal cell carcinoma.
Collins K; Hwang M; Antic T; Paintal A; Argani P; Matoso A; Gopinath A; Baskovich B; Mehra R; Williamson SR; Idrees MT; Barletta JA; Anderson WJ; Hirsch MS; Hornick JL; Acosta AM
Histopathology; 2022 Nov; 81(5):577-586. PubMed ID: 35971742
[TBL] [Abstract][Full Text] [Related]
30. "High-grade oncocytic renal tumor": morphologic, immunohistochemical, and molecular genetic study of 14 cases.
He H; Trpkov K; Martinek P; Isikci OT; Maggi-Galuzzi C; Alaghehbandan R; Gill AJ; Tretiakova M; Lopez JI; Williamson SR; Montiel DP; Sperga M; Comperat E; Brimo F; Yilmaz A; Pivovarcikova K; Michalova K; Slouka D; Prochazkova K; Hora M; Bonert M; Michal M; Hes O
Virchows Arch; 2018 Dec; 473(6):725-738. PubMed ID: 30232607
[TBL] [Abstract][Full Text] [Related]
31. [Clinicopathological characteristics of fumarate hydratase-deficient renal cell carcinoma].
Zhang W; Chu J; Zou YW; Jiang YX; Wei ZM; Zhong DC; Liu Y; Li YJ; Yu WJ
Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):120-126. PubMed ID: 30695864
[No Abstract] [Full Text] [Related]
32. Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma.
Ohe C; Smith SC; Sirohi D; Divatia M; de Peralta-Venturina M; Paner GP; Agaimy A; Amin MB; Argani P; Chen YB; Cheng L; Colecchia M; Compérat E; Werneck da Cunha I; Epstein JI; Gill AJ; Hes O; Hirsch MS; Jochum W; Kunju LP; Maclean F; Magi-Galluzzi C; McKenney JK; Mehra R; Nesi G; Osunkoya AO; Picken MM; Rao P; Reuter VE; de Oliveira Salles PG; Schultz L; Tickoo SK; Tomlins SA; Trpkov K; Amin MB
Am J Surg Pathol; 2018 Mar; 42(3):279-292. PubMed ID: 29309300
[TBL] [Abstract][Full Text] [Related]
33. Approach for reclassification of collecting duct carcinoma and comparative histopathological analysis with SMARCB1/INI1-deficient renal cell carcinoma and fumarate hydratase-deficient renal cell carcinoma.
Kiyozawa D; Kohashi K; Takamatsu D; Iwasaki T; Shibata D; Tomonaga T; Tateishi Y; Eto M; Kinjo M; Nishiyama K; Taguchi K; Oshiro Y; Kuboyama Y; Furuya M; Oda Y
Hum Pathol; 2022 Jun; 124():36-44. PubMed ID: 35306021
[TBL] [Abstract][Full Text] [Related]
34. Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: III: Molecular Pathology of Kidney Cancer.
Williamson SR; Gill AJ; Argani P; Chen YB; Egevad L; Kristiansen G; Grignon DJ; Hes O
Am J Surg Pathol; 2020 Jul; 44(7):e47-e65. PubMed ID: 32251007
[TBL] [Abstract][Full Text] [Related]
35. Reclassifying Papillary, Oncocytic and Chromophobe Renal Tumours Based on the 5 < sup > th < /sup > Who Classification 2022.
Shaikh N; Mathew M
Turk Patoloji Derg; 2024; 40(2):122-127. PubMed ID: 38265103
[TBL] [Abstract][Full Text] [Related]
36. TFE3 and TFEB-rearranged renal cell carcinomas: an immunohistochemical panel to differentiate from common renal cell neoplasms.
Caliò A; Marletta S; Brunelli M; Pedron S; Portillo SC; Segala D; Bariani E; Gobbo S; Netto G; Martignoni G
Virchows Arch; 2022 Dec; 481(6):877-891. PubMed ID: 35980471
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemistry for the diagnosis of renal epithelial neoplasms.
Akgul M; Williamson SR
Semin Diagn Pathol; 2022 Jan; 39(1):1-16. PubMed ID: 34823973
[TBL] [Abstract][Full Text] [Related]
38. Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.
Trpkov K; Williamson SR; Gill AJ; Adeniran AJ; Agaimy A; Alaghehbandan R; Amin MB; Argani P; Chen YB; Cheng L; Epstein JI; Cheville JC; Comperat E; da Cunha IW; Gordetsky JB; Gupta S; He H; Hirsch MS; Humphrey PA; Kapur P; Kojima F; Lopez JI; Maclean F; Magi-Galluzzi C; McKenney JK; Mehra R; Menon S; Netto GJ; Przybycin CG; Rao P; Rao Q; Reuter VE; Saleeb RM; Shah RB; Smith SC; Tickoo S; Tretiakova MS; True L; Verkarre V; Wobker SE; Zhou M; Hes O
Mod Pathol; 2021 Jun; 34(6):1167-1184. PubMed ID: 33526874
[TBL] [Abstract][Full Text] [Related]
39. [Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma].
Yu YF; He SM; Wu YC; Xiong SW; Shen Q; Li YY; Yang F; He Q; Li XS
Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 53(4):640-646. PubMed ID: 34393221
[TBL] [Abstract][Full Text] [Related]
40. LOT and HOT … or not. The proliferation of clinically insignificant and poorly characterised types of renal neoplasia.
Samaratunga H; Egevad L; Thunders M; Iczskowski KA; van der Kwast T; Kristiansen G; Pan CC; Leite KRM; Evans A; Clouston D; Kenwright DN; Bethwaite PB; Malone G; Wood S; Yaxley JW; Delahunt B
Pathology; 2022 Dec; 54(7):842-847. PubMed ID: 36270849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
